References
Boring CC, Squires TS, Tong T. et al. Cancer statistics, 1994. CA Cancer J Clin 1994; 44: 7–26
Seidman H, Mushinski MH, Gelb SK, et al. Probabilities of eventually developing or dying of cancer: United States. CA Cancer J Clin 1985; 35: 36–56
DeCosse JJ, Tsioulias GJ, Jacobson JS. Colorectal cancer, detection, treatment and rehabilitation. CA Cancer J Clin 1994; 44: 27–42
Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9: 138–41
Karnes Jr WE Epidemiology and etiology of sporadic colorectal adenocarcinoma. Curr Opin Gastroenterol 1994; 10: 19–26
Rosenberg L, Palmer JR, Zauber AG, et al. A hypothesis: non-steroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J Natl Cancer Inst 1991; 83: 355–8
Insel PA. Analgesic antipyretics and antiinflammatory agents: drugs employed in the treatment of rheumatoid arthritis and gout. In: Goodman & Gilman’s The pharmacological basis of therapeutics. New York: Pergamon Press, 1990: 638–81
Higgs GA, Moncada S, Vane JR. The mode of action of antiinflammatory drugs which prevent the peroxidation of arachidonic acid. Rheum Dis Clin North Am 1980; 6(3): 675–93
Brooks MP, Day RO. Nonsteroidal antiinflammatory drugs —differences and similarities. NEngl J Med 1991; 324: 1716–25
Abramson SB, Weissman G. The mechanism of action of NSAIDs. Arthritis Rheum 1989; 32: 1–9
Karmali RA. Eicosanoids in neoplasia. Prev Med 1987; 16: 493–502
Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575–89
Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122: 518–23
Kubota Y, Sunouchi K, Ono M, et al. Local immunity and metastasis of colorectal carcinoma. Dis Colon Rectum 1992; 35: 645–50
Eberhardt CE, Coffey RJ, Radhika A, et al. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183–8
Reddy BS, Sugie S. Effect of different levels of omega-3 and omega-6 fatty acids on azoxymethane-induced colon carcinogenesis in F344 rats. Cancer Res 1988; 48: 6642–7
Abramson S, Korchak H, Ludewig R, et al. Modes of action of aspirin like drugs. Proc Natl Acad Sci USA 1985; 82: 7227–31
Shiff SJ, Tsai LL, Qiao L, et al. Sulindac sulfide inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT29 human colon adenocarcinoma cells. J Clin Invest. In press
Shiff SJ, Koutsos MI, Qiao L, et al. Aspirin and other NSAIDs inhibit proliferation, alter the cell cycle distribution and induce apoptosis in HT29 colon adenocarcinoma cells. Gastroenterology. In press
Pollard M, Luckert PH. Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 1980; 64: 1323–7
Metzger U, Meier J, Uhlschmid G, et al. Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis Colon Rectum 1984; 27: 366–9
Reddy BS, Maruyama H, Kellof G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987; 47: 5340–6
Craven AP, DeRubertis FR. Effects of aspirin on 1,2-dimethyl-hydrazine-induced colonic carcinogenesis. Carcinogenesis 1992; 13:541–6
Reddy BS, Rao CV, Rivenson A, et al. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993; 14: 1493–7
Rigas B, Tsioulias GJ, Allan C, et al. The effect of bile acids and piroxicam on MHC antigen expression in rat colonocytes during colon cancer development. Immunology 1994; 83: 319–23
Waddell WR, Loughry RN. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24: 83–7
Waddell WR, Ganser GF, Cerise EJ, et al. Sulindac for polyposis of colon. Am J Surg 1989; 157: 175–9
Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635–9
Rigau J, Pique JM, Rubio E, et al. Effects of long term sulindac therapy for colonic polyposis. Ann Intern Med 1991; 115: 952–4
Giardello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313–6
Spagnesi MT, Tonelli F, Dolara P, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994; 106: 362–6
Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer 1988; 48: 4399–404
Thun MJ, Namboodiri MM, Heath Jr CW. Aspirin use and the reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593–6
Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993; 72: 1171–7
Peleg II, Maibach HT, Brown SH, et al. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994; 154: 394–9
Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241–6
Paganini-Hill A, Chao A, Ross RK, et al. Aspirin use and chronic diseases: a cohort study of the elderly. Br Med J 1989; 299: 1247–50
Gann PH, Manson JE, Glynn RJ, et al. Low dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993; 85: 1220–4
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koutsos, M.I., Shiff, S.J. & Rigas, B. Can Nonsteroidal Anti-Inflammatory Drugs Be Recommended to Prevent Colon Cancer in High Risk Elderly Patients?. Drugs & Aging 6, 421–425 (1995). https://doi.org/10.2165/00002512-199506060-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-199506060-00001